In order to study
Abstract.
In RECENTLY, we have suggested that there are TRH-related and dopamine-related pituitary TSH and PRL-pools in patients with prolactinoma and normal female subjects, and also suggested that TRH and sulpiride (DA D2 receptor antagonist) modulate these hormone pools through a different intracellular transduction mechanism [1] . In rat and human thyrotrophs and lactotrophs, the mode of action of TRH and sulpiride might be different, i.e. TRH has been thought to act on the phosphatidyl-inositol-protein kinase C system and sulpiride to act on the adenylate-cyclase-protein kinase A system by suppressing the inhibitory GTP binding protein (Gi) which is stimulated by dopamine (DA) [2] [3] [4] [5] [6] [7] [8] 
Discussion
In this study, normal female subjects showed an additive PRL response to the simultaneous administration of TRH and sulpiride, but no such response was observed in TSH. The enhanced response due to TRH and sulpiride indicates that the sites of action of these agents are different, since the doses of TRH and sulpiride are considered to be maximal [1, 9, 10] .
In in vitro studies on rat and human pituitary cells, TRH stimulates TSH and PRL secretion through the phosphatidylinositol system [2] [3] [4] [5] [6] [7] , while DA mainly inhibits TSH and PRL secretion by stimulating the inhibitory GTP binding protein (Gi) and inhibiting the subsequent cAMP-protein kinase A system [2, 4, 7, 8] . The DA antagonist therefore stimulates the cAMP-protein kinase A system by inhibiting the DA action, although we must consider the possibility that DA can also act on a number of other transduction mechanisms such as IP3 and arachidonic acid generation, and intracellular calcium concentrations [11] [12] [13] [14] . Regarding the pituitary cells, it is reported that simultaneous stimulation of different second messenger systems synergistically enhances the hormone secretion (so-called cross talking) [15] [16] [17] [18] [19] [20] [21] . However, simultaneous administration of TRH and DA antagonist in our study did not result in any synergism in PRL or TSH response in normal females, only enhanced responses compared to the single administration of these agents.
It is conceivable that TRH and sulpiride stimulate PRL secretion through different intracellular mechanisms without having distinct interactions. This is inconsistent with the fact that DA withdrawal (causing inactivation of Gi and resultant activation of the adenylate cyclase-protein kinase A system) in estrogen treated rats is known to synergistically potentiate the PRL-releasing action of TRH [20] . The reason for such a discrepancy between man and rat is not yet clear.
In this study, the simultaneous administration of TRH and sulpiride did not cause enhanced TSH response, which was quite different from prolactinoma patients. This may mean that hypothalamic DA tone is lower in normal subjects than in prolactinoma patients, and DA-related TSH pools in their thyrotrophs and the response to sulpiride are subtle [1, 22] .
Sulpiride does not increase TSH secretion in hypothalamic disorders with hyperprolactinemia, and it can differentiate prolactinoma from those disorders [23] . Further, as the combined administration of sulpiride and TRH causes clearer TSH increments probably only in prolactinoma patients, such an aberrant TSH response to sulpiride alone and to the combined administration of sulpiride and TRH would be a very useful indicator for the differential diagnosis of hyperprolactinemia [1] .
In conclusion, the intracellular transduction mechanisms of TRH and sulpiride might be different from each other, and these agents work additively but not synergistically in human lactotrophs.
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